Ireland's first 'celebrity chef' will appeal to politicians to deal with the "over-regulation" of the food industry."I...
A State compensation scheme is being considered for the victims of a devastating sleeping disorder linked to the swine...
The Social Media MBA By Christer HollomanCHRISTER Holloman has edited rather than written this insight into how corporations...
The FBI has told Scotland Yard it is "prepared to step in" if the Metropolitan Police fails to investigate the full extent...
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
Flook covers technology, biotech and venture capital. GlaxoSmithKline said Wednesday that Human Genome Sciences Inc. will need to drop a “poison pill” provision for the takeover of the Rockville biotech to move forward. Human Genome Sciences is... Full Article at Washington Business Journal
Follow him on Twitter cbaysden. GlaxoSmithKline employs about 4,500 at its U.S. headquarters in RTP. The back and forth maneuvers regarding GlaxoSmithKline’s $2.6 billion bid for Human Genome Sciences continued Wednesday, with GSK amending the... Full Article at Triangle Business Journal
LONDON, UNITED KINGDOM - MAY 15: GlaxoSmithKline Chief Executive Andrew Witty poses with his medal after being honoured with a Knighthood by Prince Charles, Prince of Wales at an Investiture ceremony at Buckingham Palace on May 15, 2012 in London,... View Photo »
Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics,... Full Article at Freshnews.com
(Reuters) - GlaxoSmithKline said it would not proceed with its $2.6 billion offer for Human Genome Sciences unless the U.S. biotechnology company dropped a "poison pill" shareholder rights plan imposed to block the deal. Human Genome adopted the... Full Article at Hartford Courant
MARK SCOTT LONDON — The British drug maker GlaxoSmithKline changed the terms of its $2.59 billion proposed takeover of Human Genome Sciences on Wednesday in response to the biotechnology company’s shareholder rights plan, or poison pill. Last week,... Full Article at The New York Times
In a file picture taken on July 13, 2011 News International Chairman and Chief Executive James Murdoch arrives for work in east London. James Murdoch, at the centre of the phone hacking scandal in his family's British newspaper business, has resigned... View Photo »
In contrast, Novartis ('AA'/Stable), Sanofi ('AA-'/ Stable), GlaxoSmithKline ('A+'/Stable) and Bayer ('A-'/Stable) have less headroom within their current ratings to pursue debt-financed investments
LONDON (Reuters) - GlaxoSmithKline (GSK.L) said it amended the conditions of its tender offer to acquire U.S. biotechnology company Human Genome Sciences (HGSI.O) in an attempt to address the target company's rights plan, which GSK called a "poison pill". Full Article at Reuters Mobile
Because HGS has adopted a poison pill, GSK has added a condition to its offer requiring HGS to redeem the pill or, alternatively, GSK being satisfied in its reasonable judgment that the pill has been invalidated or is otherwise inapplicable to GSK's... Full Article at Benzinga.com
PLC (GSK) - GSK amends HGS tender offer conditions RNS Number : 9539D GlaxoSmithKline PLC 23 May 2012 Issued: Wednesday 23 May 2012, London UK GSK amends tender offer conditions to address Human Genome Sciences' adoption of poison pill... Full Article at Bloomberg.com
There are no results for this module. Edit this module to change the search term used to query Wikipedia
In contrast, Novartis ('AA'/Stable), Sanofi ('AA-'/ Stable), GlaxoSmithKline ('A+'/Stable) and Bayer ('A-'/Stable) have less headroom within their current ratings to pursue debt-financed investments
world's largest research-ba... We have posted multiple times about Avandia (rosiglitazone), GlaxoSmithKline's star-crossed glucose-lowering drug. While Avandia has receiv... From the aforementioned Huffington Post Investigative Fund article
GlaxoSmithKline (NYSE: GSK ) made an offer; we think it's too low; we'll look for higher offers and let you know when we have one.
GlaxoSmithKline's mission of helping people do more, feel better and live longer is achieved not just through medicines and vaccines, but also through employee involvement
As a company with a long-term commitment to sustainability, GlaxoSmithKline is proud to support the 2012 Green Plus Awards ... The Green Plus Award Winners demonstrate that sustainability can be a catalyst for innovation in any industry.
You have GlaxoSmithKline, one of the world's biggest companies, one of the great British success stories, saying the Budget has changed their view of Britain as a place to invest
that he has lectured and consulted for Pfizer and has served as an investigator on research studies at the University of Wisconsin (UW) that were supported by GlaxoSmithKline, Nabi, Pfizer, and sanofi-aventis.
We are delighted by the decision of GlaxoSmithKline and Janssen to participate in this fund. The fact that these two global pharmaceutical leaders are committing substantial resources to seek early-stage opportunities through a pure-play classic Venture Capital fund is a testament to the visionary leade...
A well-loved M2W® speaker, Mary Lou is a globally recognized authority on what women want. With Just Ask a Woman she advised over 100 blue chip brands including: Wells Fargo, Pepsi, GlaxoSmithKline, and KAO Brands, among others ... Plus Mary Lou comes bearing gifts! Everyone who attends the conference w...
The decision will aid Irvine’s case for accommodating the potential investment by GlaxoSmithKline in a biopharmaceutical manufacturing operation as an extension to their existing plant.
It is quite obvious to me that James Murdoch, Brian Deer and GlaxoSmithKline orchestrated the smear attack on Dr. Andrew Wakefield
The legacy project is a key aspect of Montrose 450 ... Thanks to funding by GlaxoSmithKline, junior golfers won’t have to pay to use the pitch-and-putt course, which should help to ensure Montrosians’ 450-year love affair with golf continues for another 450 years.
A.M. Vitals: Daiichi Sankyo, GlaxoSmithKline Form Vaccine Venture
GlaxoSmithKline Pharma expects 40% of its sales to be impacted if the policy is implemented in its current form. Overall the company expects to grow in-line with the industry growth average going ahead.
- GTATopEmployers
4 hours ago
- GTATopEmployers
4 hours ago
- GTATopEmployers
6 hours ago
- Bilingual__Jobs
1 day ago
- GTATopEmployers
1 day ago
There are no results for this module.
A fresh, fun site featuring celeb gossip, fashion, beauty, love & sex, and health & fitness.
©Independent.ie Back to top